Celgene has presented Phase III data showing a significant progression-free survival (PFS) benefit in patients with multiple myeloma taking a triple combination therapy of Imnovid, Velcade and low-dose dexamethasone.
Read More
Myeloma UK has launched a nationwide trial aiming to assess the effectiveness of a novel treatment combination that includes Darzalex for patients with genetically-defined high-risk myeloma.
Read More
EU regulators have expanded the scope of Janssen’s Darzalex to include patients with multiple myeloma who have received at least one prior therapy, when given in combination with lenalidomide and dexamethasone, or bortezomib (Velcade).
Read More
